Save Recarbrio as a Last Resort for Resistant Infections

February 2020

Recarbrio (reh-CAR-bree-oh, imipenem/cilastatin/relebactam) is a new combo antibiotic for resistant gram-negative infections.

It follows in the footsteps of other novel, broad-spectrum beta-lactamase inhibitor combos...such as Vabomere (meropenem/vaborbactam) and Avycaz (ceftazidime/avibactam).

Relebactam is a beta-lactamase inhibitor that restores imipenem's activity against organisms, such as resistant Pseudomonas or common carbapenem-resistant Enterobacteriaceae (CRE).

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Seizures Consider Levetiracetam for Benzo-Resistant Status Epilepticus
New Drugs Save Recarbrio as a Last Resort for Resistant Infections
Emergency Medicine Be Ready to Manage Symptoms of Stimulant Toxicity
CPR Don't Expect to Add the Antiarrhythmic Bretylium to Crash Carts
Med Administration Know Whether to Redose Meds After Vomiting
New Drugs Expect Trikafta to Be a Game Changer for Cystic Fibrosis
Cardiology Help With Proper Use of Colchicine for Pericarditis
Hepatitis C Try to Limit Interruptions of Hep C Antivirals
New Drugs Watch for Patients on the Parkinson's Med Nourianz
Med Safety Recommend Eye Exams for Patients on Elmiron at Home

Save Recarbrio as a Last Resort for Resistant Infections

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents